Business Wire

Travelxp 4K Joins SES Ultra HD Line-up in North America

Del

SES S.A. (Euronext Paris:SESG) (LuxX:SESG) today announced that Travelxp 4K, an international travel channel, will make its Ultra HD debut next month on SES’s growing Ultra HD distribution platform serving cable operators and multichannel television platforms throughout North America.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161218005060/en/

Offering audiences compelling stories from faraway places, the world’s first 4K travel channel, Travelxp 4K, is set to launch on the SES-1 satellite, one of a trio of SES satellites (SES-1, SES-3, AMC-18) that are home to the region’s leading Ultra HD distribution platform. Travelxp 4K, licensed to multichannel video program distributors (MVPDs) by Vivicast Media, is the latest in a series of Ultra HD channels to join SES’s Ultra HD platform, home to nine linear Ultra HD channels as of January. SES has now signed distribution agreements with more than 30 Ultra HD channels globally, of which 21 are commercial.

Travelxp 4K, a venture of Celebrities Management Private Limited in India, features hundreds of hours of world class travel programs filmed all over the world. The 4K channel follows the success of Travelxp HD, which offers 100% originally-produced premium travel and lifestyle programming distributed to over 50 million homes globally. Travelxp 4K will showcase global travel content with breathtaking images in 10 bit REC2020 color space with HLG (Hybrid Log Gamma) HDR (High Dynamic Range).

“Travelxp 4K is all about bringing the world to homes in stunning resolution. 10 bit REC2020 with HLG HDR will make the viewing experience more immersive and vivid. It’s not just about more pixels in 4K but better pixels,” explained Prashant Chothani, CEO, Travelxp 4K. “We are delighted to offer viewers a closer and more fascinating look at the world’s most beautiful travel destinations, cultures, and heritage like never before with our 100% original and exclusive 4K programming. By joining SES’s growing Ultra HD bouquet and content distribution platform, Travelxp 4K is well-positioned to reach significant audiences across North America.”

“SES has created the best and largest bouquet of stunning 4K programming in a single location around the world,” said Steve Corda, Vice President of Business Development in North America for SES. “People across the U.S. and North America are purchasing Ultra HD TVs at a record pace, with a surge expected this holiday season. Millions of television viewers are now expecting to watch 4K programming on their new screens, and cable operators and other television platform providers are on the verge of satisfying this growing demand with the historic home delivery of linear Ultra HD in the coming weeks and months.”

Follow us on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: https://www.ses.com/news/blogs
SES White papers are available under https://www.ses.com/news/whitepapers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at: www.ses.com.

About Celebrities Management Private Limited

Celebrities Management Private Limited is a privately held company in India, with interest in broadcast, advertising, media consulting and other related services. The company operates 7 (seven) satellite channels across the globe across its group companies.

Further information available at: www.travelxp.tv

About Vivicast Media

Vivicast Media is a leading source of the finest quality 4K programming and 24/7 linear networks. As a forward-thinking media company, Vivicast was one of the first companies to offer linear content geared toward the OTT market and has shown that same commitment to 4K/Ultra HD. Vivicast Media is a one-stop source of the very best 4K content the entertainment business has to offer.

Further information available at: www.vivicast.com

Contact information

For further information please contact:
SES S.A.
Markus Payer, +352 710 725 500
Corporate Communications
Markus.Payer@ses.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33Pressemelding

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

CTS Engines Announces Senior Management Hire12.12.2017 13:00Pressemelding

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00Pressemelding

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom